Skip to main content

Falcon Technologies, Inc


OTC: FLCN

Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) OTC:FLCN is a nutraceutical company developing a range of CBD-based products. The company's mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.
 

Company Website:  Under Construction

Security Details


Authorized Shares:        100,000,000
 

Outstanding Shares        19,531,847


Float                                    5,086,101
 

Information from OTC Markets 


The Opportunity

The CBD industry will quickly become a Multi-Billion Dollar sector in short order.   Investing in early stage companies that are positioning themselves to capture a part of this market is a wise investment for future high returns.  FLCN is one of those companies.   The strategic direction of FLCN will position the business in a very profitable situation based on early projections.    We believe that an investment at this level could return exponential gains over the next few months and definitely the next few years.   We encourage you to do your own due diligence on this exciting company.   

In the NEWS


Falcon Technologies Announces the Filing of a Trademark Application for a Dietary Supplement for the Pet Market with Plans to Launch CBD Brand for PetsPress Release | 07/24/2019

SACRAMENTO, CA / ACCESSWIRE / July 24, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN), a company focused on the marketing, sale, and distribution of CBD products and other products derived from industrial hemp announced today that it has filed a trademark application with the United States Patent and Trademark Office for a new dietary supplement for pets. The trademark has been filed as a result of Falcons ongoing efforts to work with professionals to launch quality CBD products.

According to the American Pet Products Association, pet owners spent more than $72 billion on their pets in 2018. As the global pet care market continues its meteoric rise, all reports point to the fact that CBD-infused pet products will represent the highest compound annual growth rate (CAGR) in the global market for pet products.

The market for human CBD products has been growing for about a decade. However, the market for pet products infused with CBD is just beginning to grow. Sixty-eight percent of all U.S. households have at least 1 pet which equates into 85 million families. That number is up from 56 percent of all households in 1986.

CBD ( Cannabidiol ) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess a variety of therapeutic properties.

William Delgado, Chairman and Chief Executive Officer of Falcon Technologies commented, The trademark application should give our shareholders and all investors a hint about what our plans are. We are fully committed to working with top professionals to build brands that represent honesty, quality, reliability, integrity and sustainability. Going forward, we are committed to the pet market as well as the human market to build successful CBD brands.

Mr. Delgado added, We will be announcing further details about the trademark application and our plans for the CBD pet market shortly.




Dr. Tin-Chuen Yeung, Distinguished Former Director of Strategy and Business Development at Baxter Healthcare Accepts Position as Advisory Panel Member of Falcon TechnologiesPress Release | 06/11/2019

SACRAMENTO, CA / ACCESSWIRE / June 11, 2019 / Falcon Technologies, Inc. (OTCPINK: FLCN), a company focused on the marketing, sale, and distribution of CBD products and products derived from industrial hemp is honored Dr. Tin-Chuen Yeung has formally accepted a position on its Scientific Advisory Board.

Dr. Yeung is a pharmacologist and an experienced researcher in the healthcare industry. Besides his experience in research, he has substantial experience in intellectual property law, business development, technology evaluation and commercialization. He serves as an advisor to venture capital and start-up biotechnology companies throughout the United States. He has also served as a trusted advisor to Fortune 500 companies.

Dr. Yeung is currently the President of Everest International, Inc., where he provides consulting services in management of intellectual property, patent filing and prosecution, intellectual property, due diligence for M&A's, technology licensing, technology commercialization, and business development.

Dr. Yeung is formerly the Head of Strategic Development, Life Sciences, for the Chicago law firm Bell Boyd & Lloyd, LLC. He is admitted to practice patent law before the United States Patent Bar. At Bell Boyd & Lloyd, he was also with the Intellectual Property group responsible for patent prosecution in the areas of biotechnology, nanotechnology, agricultural biotechnology, pharmaceuticals, drug delivery technologies, medical devices and other life sciences. He also provides counseling to clients in patent filing strategies and management of intellectual property.

Dr. Yeung served as a Director of Strategy & Business Development for the Biosciences Division at Baxter International, Inc., where he managed the strategic development for worldwide development, marketing and manufacturing of recombinant protein products. He also served as Director of Corporate Development for Baxter, responsible for management of Baxter's acquisitions, technology development, licensing, and strategic alliances.

Dr. Yeung also worked for the G. D. Searle and NutraSweet Divisions of the Monsanto Company (MON) for several years as a research scientist, and as manager of business ventures managing the evaluation and commercialization of new technologies. Prior to joining Monsanto, he was a research fellow at Harvard Medical School, Department of Pharmacology, studying the mechanisms of action and toxicity of anti-cancer drugs.

Dr. Yeung received a Bachelor of Science in Biochemistry and Doctor of Philosophy and Pharmacology degrees from the State University of New York and a Master of Management from Northwestern University's Kellogg Graduate School of Management with concentrations in Finance, Marketing, and Management of Information Systems.

"Dr. Yeung's credentials are too numerous to name. Not only does Dr. Yeung have an impeccable background and reputation, Dr. Yeung may be one of few people in the United States who can say he has a doctoral degree in pharmacology, an MBA, a biotechnology business development background, and the expertise and knowledge to practice patent law before the United States Patent Bar," said William Delgado, Chairman and CEO of Health Discovery Corporation.

Mr. Delgado added, "Dr. Yeung will bring significant product development expertise to our team of Scientific Advisors as we move to create a real scientific team and a real body of data behind our line of hemp-derived products. Falcon fully expects to be a leader in the research, development and commercialization of cannabinoid-based dietary supplements and medicines."

Dr. Yeung commented, "I believe that the potential to help people with supplements and medicines using cannabinoids found in hemp and cannabis is very real and is one of the more exciting developments in human healthcare that we have seen in decades. I look forward to working with Bill and his team."



Falcon Technologies Announces the Filing of a Provisional Patent Application for CBD Formulations to Treat Ulcers

SACRAMENTO, CA / ACCESSWIRE / April 25, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office. The invention is titled "CBD Formulations to Treat Peptic and Gastrointestinal Ulcers".

The pharmaceutical and OTC drug markets to treat ulcers is one of the largest medical markets in the United States. Approximately 4% of all adult Americans suffer from peptic (also called gastrointestinal) ulcers. Peptic ulcers can occur in the stomach, the intestines and even parts of the esophagus. This invention covers all non-cancerous ulcers that occur in the stomach, the intestines and even parts of the esophagus. The most common causes of peptic ulcers are infection with the bacterium Helicobacter pylori (H. pylori) and long-term use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) (Advil, Aleve, others).

The provisional patent application number is 62838236. At this time, Falcon will not reveal any details about the provisional patent application except for the fact that the formulation contains CBD and an off-patent ingredient from one of the most well known and well-documented healthcare products in the entire world. The purpose and goal of the patent is to secure patent protection now to operate in what is another multi-billion-dollar market.

This provisional patent application follows Falcon's recent provisional patent application to treat acne with certain CBD formulations. The latest provisional patent application continues Falcon's strategy to gain advantages over potential competition. These advantages may be marketing and sales advantages or formulation advantages such as the one covered by this provisional patent application.

William J. Delgado, Chairman and Chief Executive Officer of Falcon Technologies stated, "We are ecstatic that we can deliver this great news to our shareholders. We are working diligently to gain an advantage over the other companies currently selling CBD products and this second provisional patent application is another example of the progress we are making with our overall corporate strategy."

CBD ( Cannabidiol ) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess a variety of therapeutic properties.

 


Falcon Technologies Comments on CVS Now Selling CBD Products in Select Stores in the United StatesPress Release | 04/17/2019

SACRAMENTO, CA / ACCESSWIRE / April 17, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN), a company focusing on the marketing, sale, and distribution of CBD products and products derived from industrial hemp such as protein powder, hemp seeds and hemp oil has commented on the recent news that CVS began selling topical CBD products.

Universally known as CBD, Cannabidiol (the scientific name for CBD) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess a variety of therapeutic properties.

The 2018 Farm Bill legalized industrial hemp, removing this plant rich in CBD and nutritional supplements from the Controlled Substance Act and categorizing it as an agricultural commodity. This bill will allow states to regulate hemp farming while moving the industrialization of the hemp plant forward. As industrial hemp once again becomes one of America's most popular agricultural crops, the amount of CBD processed from the plant will grow exponentially. The hemp-CBD market is projected to grow from $600 million in 2018 to $22 billion by 2022.

Over the past week, CVS, one of North America's largest drug store chains began selling topical CBD products. In an interview with CNBC's Jim Cramer, CVS CEO Larry Merlo commented on CVS now selling CBD products, "We're going to be carrying them in 8 states. We're going to be carrying the topical products only. " Merlo added, "Anecdotally, we've heard from our customers that have used those products, it's helped for pain relief, arthritis and other ailments. We're going to walk slowly but we think this is something the customers are going to be looking for as part of the health offering."

William Delgado, Chairman and Chief Executive Officer of Falcon Technologies commented, "We applaud CVS's entry into the CBD market. Several weeks ago, we announced that we filed a provisional patent application titled "CBD Formulations to Treat Acne". We are also working diligently behind the scenes to create CBD formulations for other skin conditions."

Delgado added, "It is critically important that our shareholders and investors understand we are one step ahead. The whole world is focusing on CBD topical formulations for pain. We believe it goes well beyond that and we will be announcing additional progress and CBD topical formulations over the next few weeks and months."





Falcon Technologies Announces the Signing of an Exclusive 2 Year Worldwide License with Publicly-Traded Stevia Corp. to Sell, Market, and Distribute Hemp Products Using the Real Hemp(TM) Brand with an Option to PurchasePress Release | 04/10/2019

SACRAMENTO, CA / ACCESSWIRE / April 10, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN) (OTC PINK: STEV) announced today that it has signed an exclusive worldwide license to use the Real Hemp trademark and brand to market, sell and distribute any dietary and nutritional supplements containing any constituents of the hemp plant for the next 2 years. As part of this license, Falcon Technologies will have an option to buy the trademark and all the rights to the brand during the license term. As a result of the vision of Stevia Corp.'s Chairman George Blankenbaker, Real Hemp LLC (Stevia Corp.'s wholly owned subsidiary), achieved trademark status and full trademark registration on July 7, 2015 before the cultivation of hemp products became completely legal in the United States.

The licensing agreement will provide Falcon with exclusive rights to use all product images, design, and graphics, product packaging, any existing social media accounts, any related printed, electronic, and online documentation, any graphic files for product packaging, and any software files that may accompany the product.

Up until a few short months ago, most hemp products on shelves in the United States were imported into the United States. However, the 2018 Farm Bill legalized the cultivation of industrial hemp and removed it from the list of controlled substances.

Industrial hemp contains all of the cannabinoids in medical marijuana but unlike marijuana, industrial hemp is low in THC (tetrahydrocannabinol - the psychoactive component in marijuana). Some strains of industrial hemp are also rich in CBD (cannabidiol), the cannabinoid which has been featured in hundreds of news stories for its therapeutic potential to potentially treat serious medical ailments such as epilepsy, cancer, pain, arthritis, and many others.

The hemp seed and the oil derived from the seed is an excellent source of protein and essential fatty acids. Three tablespoons of hemp seeds contain about 10 grams of protein. The protein from the hemp plant is a more complete protein than proteins found in red meat, chicken and fish. Hemp seeds are sold in national health food and supplements retailers. The stalk of the hemp plant contains two types of fiber. The outer fiber can be processed into long strands which can then be used for textile manufacturing. The inner core which resembles wood can be used for animal bedding. The hemp stalk can also be used as a key component in the manufacturing of paper.

There are few dominant hemp product brands in North America today. Stevia Corp. has worked tirelessly to build the Real Hemp brand and trademark for the past 3 years. Led by George Blankenbaker who served as Vice President and Director of the U.S. Hemp Roundtable and was a founding member, Director and Vice President of the U.S. Hemp Farming Alliance and a longtime member of the Hemp Industries Association, the Real Hempbrand is perfectly positioned to become a leader in the hemp products market which is expected to grow exponentially in the United States now that the cultivation of hemp is legal throughout the United States.

William J. Delgado, Chairman and Chief Executive Officer of Falcon Technologies commented, ''We are beyond ecstatic that Stevia Corp. has given us this vote of confidence to license the exclusive rights to use the Real Hempbrand for the next 2 years. George and his team have done a fantastic job in building the Real Hemp brand which we believe has the potential to be the number 1 hemp products brand in the United States.''

George Blankenbaker, Chairman and Chief Executive Officer of Stevia Corp. said, ''This is a win-win for both companies. If the result is what both companies believe the result can potentially be, Falcon will own a leading brand representing quality and health in a fast emerging market generating millions in revenue while enabling Stevia Corp. to become debt free as a result of the licensing royalty payments and potential outright purchase of the brand.''

Falcon Technologies Announces Formation of Scientific Advisory PanelPress Release | 05/29/2019

SACRAMENTO, CA / ACCESSWIRE / May 29, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN) announced today that it has formed a Scientific Advisory Panel to guide the company in advanced product development, intellectual property protection, clinical research and licensing agreements as the company continues to unveil its business plan. The members of the company's Scientific Advisory Panel have unparalleled scientific expertise. They also have significant commercialization experience in healthcare products that are currently sold in the United States.

Falcon Technologies is a public company focused on the marketing, sale, and distribution of CBD products and products derived from industrial hemp. The Agriculture Improvement Act of 2018, Public Law 115-334 (the 2018 Farm Bill), which, among other things removed the plant Cannabis sativa L. or "hemp" from the Controlled Substances Act has dramatically increased the need for CBD science and and to educate the public on CBD products such as the ones Falcon are developing. The 2018 Farm Bill has also dramatically increased the demand for hemp-derived products. Falcon is 100 percent focused on the development, marketing and sale of CBD products and hemp-derived products.

William J. Delgado, Chairman and Chief Executive Officer of Falcon Technologies stated, "I believe we will surprise our shareholders with the world class background and experience of the individuals that have agreed to join our Advisory Panel. In the world of cannabis and industrial hemp, it is important that we have advisors who have experience running some of the largest healthcare companies and institutions in the world. These are high quality individuals with impeccable credentials that will provide Falcon with invaluable experience from running the titans of healthcare whether that experience came from the commercial sector or the academic sector."